Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-549
Closed -$13.3K 266
2025
Q2
$13.3K Buy
+549
New +$12.8K ﹤0.01% 184
2024
Q3
Sell
-12,469
Closed -$349K 127
2024
Q2
$349K Buy
12,469
+2,200
+21% +$60.6K 0.09% 90
2024
Q1
$285K Buy
+10,269
New +$285K 0.07% 105
2023
Q4
Sell
-7,289
Closed -$242K 134
2023
Q3
$242K Sell
7,289
-320
-4% -$11.3K 0.08% 109
2023
Q2
$279K Buy
+7,609
New +$296K 0.05% 97
2022
Q1
Sell
-6,022
Closed -$356K 163
2021
Q4
$356K Buy
6,022
+334
+6% +$16.5K 0.11% 101
2021
Q3
$245K Hold
5,688
0.08% 102
2021
Q2
$223K Sell
5,688
-146
-3% -$5.68K 0.07% 118
2021
Q1
$211K Sell
5,834
-82
-1% -$2.91K 0.07% 110
2020
Q4
$218K Buy
+5,916
New +$217K 0.07% 105

Other funds holding PFE

GFG Capital's PFE Position: Q3 2025 in Review

GFG Capital sold out of Pfizer (PFE) in Q3 2025, closing a stake of 549 shares — an estimated $13.3K sold.

GFG Capital first reported a position in PFE in Q4 2020 and held it in 10 quarters. The position peaked at $356K in Q4 2021. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • GFG Capital reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • GFG Capital sold 549 Pfizer shares in Q3 2025, an estimated $13.3K.
  • GFG Capital first reported a position in Pfizer in Q4 2020 and held it in 10 quarters.
  • GFG Capital's Pfizer position peaked at $356K in Q4 2021.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.